Henning Gieseler
Research Subjects
Henning Gieseler has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Florian Johann
Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Pharmaceutics and Biopharmaceutics, Freeze Drying Focus Group (FDFG), Cauerstraße 4, 91058 Erlangen, Germany; Merck KGaA, Global CMC Development, Frankfurter Straße 250, 64293 Darmstadt, Germany
4 shared publicationsMichael J. Pikal
School of Pharmacy, University of Connecticut
4 shared publicationsAlbertina Arien
Janssen Pharmaceutical Research and Development, A Division of Janssen Pharmaceutical NV, 2340 Beerse, Belgium
3 shared publications- Geoffrey Lee
Division of Pharmaceutics, Friedrich-Alexander-University ErlangenGermany
3 shared publications Jakob Beirowski
Division of Pharmaceutics, Freeze-Drying Focus Group, University of Erlangen Cauerstraße, 91058 Erlangen, Germany
3 shared publications- Jakob W. Buecheler
Department of Pharmaceutics, Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Freeze Drying Focus Group (FDFG), Cauerstrasse 4, 91058 Erlangen, Germany; Chemical and Pharmaceutical Development, Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
3 shared publications
Latest Publications
- Open Access
- 27 April 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2443-2453
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads
- 27 April 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2443-2453
Open AccessEvaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads
- Open Access
- 26 April 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2433-2442
“Negative” Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody–Drug Conjugates
- 26 April 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2433-2442
Open Access“Negative” Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody–Drug Conjugates
- 12 March 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (5) , 1177-1189
Features in Backgrounds of Microscopy Images Introduce Biases in Machine Learning Analyses
- 12 March 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (5) , 1177-1189
Features in Backgrounds of Microscopy Images Introduce Biases in Machine Learning Analyses
- 7 December 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (5) , 1265-1274
Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates
- 7 December 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (5) , 1265-1274
Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates
- Open Access
- 1 February 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (2) , 212-220
Stability of freeze-dried products subjected to microcomputed tomography radiation doses
Objectives: Microcomputed tomography (µCT) is a powerful analytical tool for non-invasive structural analysis. The stability of drug substances and formulations subjected to X-ray radiation may be a concern in the industry. This study examines the effect of X-ray radiation on the stability of freeze-dried pharmaceuticals. The investigation is a proof of concept study for the safety of µCT X-ray radiation doses during the non-destructive investigation of freeze-dried products. Methods: Different formulations of clotrimazole, insulin and l-lactate dehydrogenase were freeze-dried and the products exposed to a defined dose of radiation by µCT. Conservative freeze-drying conditions were used. Irradiated and normal samples were analysed for their stability directly after freeze-drying and after stability testing. Key findings: The stability of model compounds was well maintained during freeze-drying. Some degradation of all compounds occurred during accelerated stability testing. The results showed no differences between the irradiated and normal state directly after freeze-drying and accelerated stability testing. Conclusions: No evidence of a detrimental effect of 100 Gy X-ray exposure on a model small molecule, peptide and protein compound was found while useful structural information could be obtained. Consequently, the technology may be useful as a non-destructive tool for product inspections if the formulation proves stable.
- 1 February 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (2) , 212-220
Open AccessStability of freeze-dried products subjected to microcomputed tomography radiation doses
Objectives: Microcomputed tomography (µCT) is a powerful analytical tool for non-invasive structural analysis. The stability of drug substances and formulations subjected to X-ray radiation may be a concern in the industry. This study examines the effect of X-ray radiation on the stability of freeze-dried pharmaceuticals. The investigation is a proof of concept study for the safety of µCT X-ray radiation doses during the non-destructive investigation of freeze-dried products. Methods: Different formulations of clotrimazole, insulin and l-lactate dehydrogenase were freeze-dried and the products exposed to a defined dose of radiation by µCT. Conservative freeze-drying conditions were used. Irradiated and normal samples were analysed for their stability directly after freeze-drying and after stability testing. Key findings: The stability of model compounds was well maintained during freeze-drying. Some degradation of all compounds occurred during accelerated stability testing. The results showed no differences between the irradiated and normal state directly after freeze-drying and accelerated stability testing. Conclusions: No evidence of a detrimental effect of 100 Gy X-ray exposure on a model small molecule, peptide and protein compound was found while useful structural information could be obtained. Consequently, the technology may be useful as a non-destructive tool for product inspections if the formulation proves stable.
- 25 October 2018
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 73 (2) , 111-120
Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals
The capping of vials plays a critical role in drug product manufacturing process due to its complex interplay of several adjustable process steps. Seal quality, integrity and assurance of containment is essential for parenteral pharmaceuticals as the vial’s content may be contaminated, or in case of highly potent drugs (e.g. antibody drug conjugates) may bear a risk of contamination. The residual seal force (RSF) method can enable further insight in capping equipment settings independently of the container closure system (CCS) and their resulting seal quality. The present study investigates the accuracy of the RSF method focusing on different force settings, RSF development over time, distance between capping plates and vial neck (roller-axis), time point of flip-off button removal and internal and external vial pressure differences (flight simulation and vials closed under vacuum). Results show that the forces used on a RSF tester should be kept low to minimize deformation of the CCS and a period of stable RSF values after the initial decrease should be implemented between capping and RSF measurement to increase accuracy. Variations in the distance between the capping plates and vial neck (roller-axis) can result in incomplete crimps, or visual defects of the seals. Additionally, the time point of removal of the flip-off button as part of the sample preparation had no significant impact on RSF measurements. Finally, pressure differences between the vial interior and exterior had no significant impact on the RSF data.
- 25 October 2018
- Published by Parenteral Drug Association, Inc. in PDA Journal of Pharmaceutical Science and Technology
- Vol. 73 (2) , 111-120
Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals
The capping of vials plays a critical role in drug product manufacturing process due to its complex interplay of several adjustable process steps. Seal quality, integrity and assurance of containment is essential for parenteral pharmaceuticals as the vial’s content may be contaminated, or in case of highly potent drugs (e.g. antibody drug conjugates) may bear a risk of contamination. The residual seal force (RSF) method can enable further insight in capping equipment settings independently of the container closure system (CCS) and their resulting seal quality. The present study investigates the accuracy of the RSF method focusing on different force settings, RSF development over time, distance between capping plates and vial neck (roller-axis), time point of flip-off button removal and internal and external vial pressure differences (flight simulation and vials closed under vacuum). Results show that the forces used on a RSF tester should be kept low to minimize deformation of the CCS and a period of stable RSF values after the initial decrease should be implemented between capping and RSF measurement to increase accuracy. Variations in the distance between the capping plates and vial neck (roller-axis) can result in incomplete crimps, or visual defects of the seals. Additionally, the time point of removal of the flip-off button as part of the sample preparation had no significant impact on RSF measurements. Finally, pressure differences between the vial interior and exterior had no significant impact on the RSF data.
- 29 May 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (7) , 2656-2664
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
In silico screening of toxin payloads typically employed in ADCs revealed a wide range of hydrophobicities and sizes as measured by logP and topological polar surface area (tPSA) values. These descriptors were used to identify three nontoxic surrogate payloads that encompass the range of hydrophobicity defined by the ADC toxin training set. The uniform drug to antibody ratio (DAR) ADCs were prepared for each surrogate payload by conjugation to the interchain cysteine residues of a model IgG1 subtype mAb. Linkage of these surrogate payloads to a common mAb with a matched DAR value allowed for preliminary analytical interrogation of the influence of payload hydrophobicity on global structure, self-association, and aggregation properties. The results of differential scanning fluorimetry and dynamic light scattering experiments clearly revealed a direct correlation between the destabilization of the native mAb structure and the increasing payload hydrophobicity. Also, self-association/aggregation propensity examined by self-interaction biolayer interferometry or size exclusion HPLC was consistent with increased conversion of the monomeric mAb to higher order aggregated species, with the degree of conversion directly proportional to the payload hydrophobicity. In summary, these findings prove that the payload-dependent structure destabilization and enhanced propensity to self-associate/aggregate driven by the increasing payload hydrophobicity contribute to reduced ADC stability and more complex behavior when assessing exposure and safety/efficacy relationships.
- 29 May 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (7) , 2656-2664
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
In silico screening of toxin payloads typically employed in ADCs revealed a wide range of hydrophobicities and sizes as measured by logP and topological polar surface area (tPSA) values. These descriptors were used to identify three nontoxic surrogate payloads that encompass the range of hydrophobicity defined by the ADC toxin training set. The uniform drug to antibody ratio (DAR) ADCs were prepared for each surrogate payload by conjugation to the interchain cysteine residues of a model IgG1 subtype mAb. Linkage of these surrogate payloads to a common mAb with a matched DAR value allowed for preliminary analytical interrogation of the influence of payload hydrophobicity on global structure, self-association, and aggregation properties. The results of differential scanning fluorimetry and dynamic light scattering experiments clearly revealed a direct correlation between the destabilization of the native mAb structure and the increasing payload hydrophobicity. Also, self-association/aggregation propensity examined by self-interaction biolayer interferometry or size exclusion HPLC was consistent with increased conversion of the monomeric mAb to higher order aggregated species, with the degree of conversion directly proportional to the payload hydrophobicity. In summary, these findings prove that the payload-dependent structure destabilization and enhanced propensity to self-associate/aggregate driven by the increasing payload hydrophobicity contribute to reduced ADC stability and more complex behavior when assessing exposure and safety/efficacy relationships.
- 30 January 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 70 (5) , 625-635
High-throughput oxidation screen of antibody–drug conjugates by analytical protein A chromatography following IdeS digest
Objectives: Oxidation of protein therapeutics is a major chemical degradation pathway which may impact bioactivity, serum half-life and stability. Therefore, oxidation is a relevant parameter which has to be monitored throughout formulation development. Methods such as HIC, RPLC and LC/MS achieve a separation of oxidized and non-oxidized species by differences in hydrophobicity. Antibody–drug conjugates (ADC) although are highly more complex due to the heterogeneity in linker, drug, drug-to-antibody ratio (DAR) and conjugation site. The analytical protein A chromatography can provide a simple and fast alternative to these common methods. Methods: A miniature analytical protein A chromatography method in combination with an IdeS digest was developed to analyse ADCs. The IdeS digest efficiency of an IgG1 was monitored using SEC-HPLC and non-reducing SDS-PAGE. An antibody-fluorescent dye conjugate was conjugated at different dye-to-antibody ratios as model construct to mimic an ADC. Key findings: With IdeS, an almost complete digest of a model IgG1 can be achieved (digested protein amount >98%). This enables subsequent analytical protein A chromatography, which consequently eliminates any interference of payload with the stationary phase. Conclusion: A novel high-throughput method for an interchain cysteine-linked ADC oxidation screens during formulation development was developed.
- 30 January 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 70 (5) , 625-635
High-throughput oxidation screen of antibody–drug conjugates by analytical protein A chromatography following IdeS digest
Objectives: Oxidation of protein therapeutics is a major chemical degradation pathway which may impact bioactivity, serum half-life and stability. Therefore, oxidation is a relevant parameter which has to be monitored throughout formulation development. Methods such as HIC, RPLC and LC/MS achieve a separation of oxidized and non-oxidized species by differences in hydrophobicity. Antibody–drug conjugates (ADC) although are highly more complex due to the heterogeneity in linker, drug, drug-to-antibody ratio (DAR) and conjugation site. The analytical protein A chromatography can provide a simple and fast alternative to these common methods. Methods: A miniature analytical protein A chromatography method in combination with an IdeS digest was developed to analyse ADCs. The IdeS digest efficiency of an IgG1 was monitored using SEC-HPLC and non-reducing SDS-PAGE. An antibody-fluorescent dye conjugate was conjugated at different dye-to-antibody ratios as model construct to mimic an ADC. Key findings: With IdeS, an almost complete digest of a model IgG1 can be achieved (digested protein amount >98%). This enables subsequent analytical protein A chromatography, which consequently eliminates any interference of payload with the stationary phase. Conclusion: A novel high-throughput method for an interchain cysteine-linked ADC oxidation screens during formulation development was developed.
- 1 March 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (3) , 813-826
Investigation of Histidine Stabilizing Effects on LDH During Freeze-Drying
- 1 March 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (3) , 813-826
Investigation of Histidine Stabilizing Effects on LDH During Freeze-Drying
- 17 January 2013
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 19 (2) , 137-147
Taste masking of naproxen sodium granules by fluid-bed coating
The taste of oral dosage forms is an important argument regarding patient’s compliance and acceptability. For this reason, it is often necessary to mask an undesirable and unpleasant taste of an active pharmaceutical ingredient. The purpose of this study was to mask the taste of naproxen sodium by a new fluid-bed coating approach. Different compositions of coating suspensions were used to coat naproxen sodium granules. It was found that products with the addition of a plasticizer were not stable at 40 °C and tended to agglomerate. Subsequently, formulations without plasticizer were used and the ratio between water and Eudragit® E was varied. Increasing the fraction of water in the suspension from 3% to 14% reduced the effective release of naproxen sodium. An optimum ratio between naproxen sodium granules and Eudragit® E was found to be 1:1.576, where less naproxen sodium was released than the threshold bitter value and an appropriate taste masking for more than 5 min was guaranteed. Investigation of the particle size distribution revealed a d10 of 138.35 ± 21.52 µm, a d50 = 256.40 ± 11.27 µm and a d90 = 500.85 ± 69.08 µm, which guarantees an acceptable mouthfeel for patients.
- 17 January 2013
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 19 (2) , 137-147
Taste masking of naproxen sodium granules by fluid-bed coating
The taste of oral dosage forms is an important argument regarding patient’s compliance and acceptability. For this reason, it is often necessary to mask an undesirable and unpleasant taste of an active pharmaceutical ingredient. The purpose of this study was to mask the taste of naproxen sodium by a new fluid-bed coating approach. Different compositions of coating suspensions were used to coat naproxen sodium granules. It was found that products with the addition of a plasticizer were not stable at 40 °C and tended to agglomerate. Subsequently, formulations without plasticizer were used and the ratio between water and Eudragit® E was varied. Increasing the fraction of water in the suspension from 3% to 14% reduced the effective release of naproxen sodium. An optimum ratio between naproxen sodium granules and Eudragit® E was found to be 1:1.576, where less naproxen sodium was released than the threshold bitter value and an appropriate taste masking for more than 5 min was guaranteed. Investigation of the particle size distribution revealed a d10 of 138.35 ± 21.52 µm, a d50 = 256.40 ± 11.27 µm and a d90 = 500.85 ± 69.08 µm, which guarantees an acceptable mouthfeel for patients.